Prevymis may be alternative to Valcyte for CMV-associated uveitis

SAN FRANCISCO — Prevymis safely resolved inflammation among patients with cytomegalovirus-associated uveitis, according to a presentation at the American Academy of Ophthalmology annual meeting.
“In the United States, typical treatment for cytomegalovirus (CMV)-associated uveitis is with Valcyte (valganciclovir, Genentech) 900 mg twice daily,” Edmund Tsui, MD, assistant professor of ophthalmology at the Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, told Ocular Surgery News. “Although this is an effective treatment, it